Caris Life Sciences Completes Initial Public Offering
06.23.25
This is only gets display when printing
Simpson Thacher advised Caris Life Sciences® (“Caris”) in connection with the executive compensation and employee benefits aspects of its initial public offering of 23,529,412 shares of its common stock, at a public offering price of $21 per share. The offering closed on June 20, 2025.
Caris is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare.
The Simpson Thacher team included Gillian Emmett Moldowan, Daniella Villatoro and Skyler Kanfer (Executive Compensation and Employee Benefits).